GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Novartis India Ltd

Novartis India Board Notes Novartis AG Share Sale to ChrysCapital

MANAGEMENT ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 29 Jul 2026, 08:13 PM IST  ·  BSE ID: 47185313-8ffe-4a94-bf85-42f301e31f18
View Original BSE Filing (PDF)
💡
In Simple Terms
Novartis India's directors acknowledged that Novartis AG sold over 17 million shares to ChrysCapital's investment funds.
🤖 AI Summary
  • Novartis India Board notes completion of sale of 17,450,680 shares from Novartis AG.
  • Transaction involves sale to WaveRise Investments, ChrysCapital Fund X, and Two Infinity Partners.
  • Sale follows an agreement signed on February 19, 2026, between Novartis AG and CC.
  • Board also noted resignation of Ms. Shilpa Joshi as Chief Financial Officer.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Equity Shares Sold
17,450,680
🏢 How This Affects the Company
📈
Business Impact
This transaction signals a change in significant shareholding which may impact the company's strategic direction or operational focus.
💰
Financial Impact
The financial impact on Novartis India itself is not directly detailed in this filing beyond the change in major shareholder.
⚙️
Operational Impact
No direct operational impacts are stated in the filing.
⚠️
Risk Impact
A change in major shareholder can introduce new strategic risks or opportunities depending on the new entity's objectives.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this filing.
👤
Who Is Affected
Shareholders of Novartis India are affected by the change in its largest shareholder, Novartis AG, to ChrysCapital entities.
🔍
Management Signal
The filing signals management's adherence to disclosure requirements regarding material shareholding changes.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Future announcements regarding strategic changes by new majority shareholder.
Resignation of Ms. Shilpa Joshi and appointment of new CFO.
Quarterly results to assess any business or financial shifts.
MEDIUM RISK Significant change in promoter shareholding introduces uncertainty regarding future strategy.
💡 Investor Takeaway
Novartis India's Board confirmed the completion of Novartis AG's sale of 17,450,680 equity shares to ChrysCapital entities, marking a significant shift in ownership.
📅 Company Track Record
Previous filings show Novartis India's board has also noted the appointment of an independent director for a 5-year term and the end of an incumbent director's term.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
How many shares did Novartis AG sell in Novartis India?
Novartis AG sold 17,450,680 equity shares of Novartis India to ChrysCapital entities.
Who were the buyers of Novartis India shares from Novartis AG?
The buyers were WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners, collectively referred to as CC.
When was the agreement for the sale of Novartis India shares signed?
The agreement for the sale and purchase of the shares was signed on February 19, 2026.
What else did the Novartis India Board note at its meeting?
The Board also noted the resignation of Ms. Shilpa Joshi as Chief Financial Officer.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.